PL2598526T4 - Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1 - Google Patents

Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1

Info

Publication number: PL2598526T4
Authority: PL; Poland
Prior art keywords: agonists; antagonists; receptor; type; chimeric interleukin
Prior art date: 2010-07-29

Application number

PL11749612.5T

Other languages

English (en)

Other versions

PL2598526T3 (pl

Inventor

Thomas M. Barnes

Jinzhao Hou

Bracken M. King

Original Assignee

Eleven Biotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-29

Filing date

2011-07-29

Publication date

2019-05-31

2011-07-29 Application filed by Eleven Biotherapeutics Inc filed Critical Eleven Biotherapeutics Inc

2019-02-28 Publication of PL2598526T3 publication Critical patent/PL2598526T3/pl

2019-05-31 Publication of PL2598526T4 publication Critical patent/PL2598526T4/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)

PL11749612.5T 2010-07-29 2011-07-29 Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1 PL2598526T4 (pl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US36879910P	2010-07-29	2010-07-29
US201161436184P	2011-01-25	2011-01-25
US201161436178P	2011-01-25	2011-01-25
US201161493967P	2011-06-06	2011-06-06
US201161493966P	2011-06-06	2011-06-06
EP11749612.5A EP2598526B1 (en)	2010-07-29	2011-07-29	Chimeric il-1 receptor type i agonists and antagonists
PCT/US2011/045995 WO2012016203A1 (en)	2010-07-29	2011-07-29	Chimeric il-1 receptor type i agonists and antagonists

Publications (2)

Publication Number	Publication Date
PL2598526T3 PL2598526T3 (pl)	2019-02-28
PL2598526T4 true PL2598526T4 (pl)	2019-05-31

Family

ID=44533130

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL11749612.5T PL2598526T4 (pl)	2010-07-29	2011-07-29	Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1
PL18191564.6T PL3470421T3 (pl)	2010-07-29	2011-07-29	Chimeryczne antagonisty receptora il-1 typu i

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18191564.6T PL3470421T3 (pl)	2010-07-29	2011-07-29	Chimeryczne antagonisty receptora il-1 typu i

Country Status (23)

Country	Link
US (2)	US8853150B2 (pl)
EP (3)	EP2598526B1 (pl)
JP (1)	JP6030554B2 (pl)
KR (1)	KR102080704B1 (pl)
CN (2)	CN103221422B (pl)
AU (3)	AU2011283669A1 (pl)
BR (1)	BR112013003646B1 (pl)
CA (1)	CA2806438C (pl)
DK (1)	DK2598526T3 (pl)
ES (2)	ES2701405T3 (pl)
HK (1)	HK1246327A1 (pl)
HR (2)	HRP20181446T1 (pl)
HU (2)	HUE063115T2 (pl)
IL (2)	IL224435B (pl)
LT (1)	LT2598526T (pl)
MX (1)	MX360097B (pl)
NZ (1)	NZ605928A (pl)
PL (2)	PL2598526T4 (pl)
RU (2)	RU2754957C2 (pl)
SG (1)	SG187231A1 (pl)
SI (1)	SI2598526T1 (pl)
WO (1)	WO2012016203A1 (pl)
ZA (1)	ZA201505145B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0708376D0 (en)	2007-05-01	2007-06-06	Alligator Bioscience Ab	Novel polypeptides and uses thereof
PL2598526T4 (pl)	2010-07-29	2019-05-31	Eleven Biotherapeutics Inc	Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1
WO2012103240A2 (en) *	2011-01-25	2012-08-02	Eleven Biotherapeutics, Inc.	Receptor binding agents
US20140341843A1 (en) *	2011-07-29	2014-11-20	Eleven Biotherapeutics, Inc.	Purified proteins
WO2013184938A2 (en) *	2012-06-08	2013-12-12	Alkermes. Inc.	Fusion polypeptides comprising mucin-domain polypeptide linkers
AU2015268652B2 (en) *	2012-06-08	2017-11-23	Mural Oncology, Inc.	Ligands modified by circular permutation as agonists and antagonists
CN107693781B (zh)	2013-03-13	2021-11-09	巴扎德制药公司	用于眼部递送的嵌合细胞因子制剂
JP2016520615A (ja) *	2013-05-31	2016-07-14	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
WO2014195953A1 (en) *	2013-06-05	2014-12-11	Ben Gurion University Of The Negev Research And Develpment Authority	IL-1beta-IL-1Ra CHIMERA AND METHODS OF USING THE SAME
WO2015048526A1 (en) *	2013-09-27	2015-04-02	Eleven Biotherapeutics, Inc.	Treating ocular pain
TW201538178A (zh)	2014-03-13	2015-10-16	Eleven Biotherapeutics Inc	生產於吹氣成型充塡密封容器內穩定的嵌合型細胞激素蛋白質配方之方法
EP3871682A1 (en) *	2016-10-14	2021-09-01	i.com Medical GmbH	Method for establishing, restoring, and preserving homeostasis of the ocular surface
EP3781175A1 (en)	2018-04-18	2021-02-24	i.com Medical GmbH	High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
WO2020157570A1 (en)	2019-01-31	2020-08-06	i.com medical GmbH	Hyaluronic acid for relief of idiopathic ocular pain
WO2022204267A1 (en)	2021-03-24	2022-09-29	Alkermes, Inc.	Upar antibodies and fusion proteins with the same
CN114480406B (zh) *	2021-09-16	2024-01-30	广东翠点生物科技有限公司	一种il-1信号通路响应元件及其应用
CA3245538A1 (en)	2022-03-10	2023-09-14	Buzzard Pharmaceuticals AB	INTERLEUKIN-1 TYPE 1 RECEPTOR INHIBITOR INTENDED FOR USE IN CANCER TREATMENT
WO2025024729A1 (en) *	2023-07-27	2025-01-30	Rush University Medical Center	Novel chitosan-il-36ra conjugates for adjustable, sustained release and tissue distribution

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL188266C (nl)	1975-07-29	1992-05-18	Merck & Co Inc	Werkwijze ter bereiding van een oogheelkundig inplantaat.
ZA811368B (en)	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
US5693489A (en)	1984-03-30	1997-12-02	Associated Universities, Inc.	Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5998578A (en)	1984-05-18	1999-12-07	New England Medical Center Hospitals, Inc.	Biologically active fragments of IL-1β
EP0569687B1 (en)	1984-05-18	2002-08-21	New England Medical Center Hospitals, Inc.	Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en)	1984-06-19	1996-01-16	Immunex Corporation	Homogeneous interleukin 1
DK172052B1 (da)	1984-12-21	1997-09-29	Otsuka Pharma Co Ltd	Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
US6107465A (en)	1984-12-21	2000-08-22	Otsuka Pharmaceutical Co., Ltd.	IL-1β and derivatives thereof and drugs
US5122459A (en)	1984-12-31	1992-06-16	Immunex Corporation	Gene encoding biologically active human interleukin 1
US4770781A (en)	1986-03-03	1988-09-13	Merck & Co., Inc.	Purification of human interleukin-1 species
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4883658A (en)	1986-04-28	1989-11-28	Holly Frank J	Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en)	1986-07-28	1989-02-14	Liposome Technology, Inc.	Ophthalmic liposomes
US5278151A (en)	1987-04-02	1994-01-11	Ocular Research Of Boston, Inc.	Dry eye treatment solution
US6858409B1 (en)	1988-05-27	2005-02-22	Amgen Inc.	Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
KR0148009B1 (ko)	1988-05-27	1998-08-01	그래고리 비. 아보트	인터루킨-1 억제제
US6159460A (en)	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
AU4005289A (en)	1988-08-25	1990-03-01	Smithkline Beecham Corporation	Recombinant saccharomyces
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE69032251T2 (de)	1989-02-27	1998-08-13	Massachusetts Institute Of Technology, Cambridge, Mass.	Il-1, dessen biologische aktivität inhibiert ist
US5075104A (en)	1989-03-31	1991-12-24	Alcon Laboratories, Inc.	Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
BR9007883A (pt)	1989-11-29	1992-09-29	Synergen Inc	Producao de inibidor de interleucina-1 humana recombinante
AU7683391A (en)	1990-04-27	1991-11-27	Upjohn Company, The	Modified interleukin-1 inhibitors
ZA912797B (en)	1990-05-29	1992-12-30	Boston Ocular Res	Dry eye treatment process and solution
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
WO1992013885A1 (en)	1991-02-05	1992-08-20	University Of Maryland	MODIFIED INTERLEUKIN-1$g(b)
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
EP0611302B1 (en)	1991-10-15	2000-03-29	MULLARKEY, Michael F.	Receptors for treating late phase inflammatory responses
AU2804192A (en)	1991-10-31	1993-06-07	Victoria University Of Manchester, The	Treatment of neurological conditions by an interleukin-1 inhibiting compound
HU219445B (hu)	1992-09-17	2001-04-28	Amgen Inc.	Interleukin-1 inhibitorokat tartalmazó, stabil gyógyszerkészítmények és eljárás előállításukra
SG44845A1 (en)	1993-01-12	1997-12-19	Biogen Inc	Recombitant anti-vla4 antibody molecules
US5340572A (en)	1993-02-08	1994-08-23	Insite Vision Incorporated	Alkaline ophthalmic suspensions
WO1995010298A1 (en)	1993-10-12	1995-04-20	Mary Lake Polan	Method of contraception
US5861476A (en)	1994-02-02	1999-01-19	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-1 receptor
IT1269989B (it)	1994-09-21	1997-04-16	Dompe Spa	Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6096728A (en)	1996-02-09	2000-08-01	Amgen Inc.	Composition and method for treating inflammatory diseases
US6416753B1 (en)	1996-03-15	2002-07-09	The General Hospital Corporation	Method for modulating apoptosis
US6974682B1 (en)	1996-08-26	2005-12-13	Human Genome Sciences, Inc.	Soluble interleukin-1 receptor accessory molecule
ZA9710414B (en) *	1996-11-19	1999-05-19	Schepens Eye Res Inst	Local use of IL-1RA for prophylaxis and treatment of corneal transplant rejection and other immune and inflammatory disorders of the eye
CA2272073A1 (en)	1996-11-19	1998-05-28	The Schepens Eye Research Institute, Inc.	Local use of il-1ra in corneal transplant rejection or disorders of the eye
EP1500329B1 (en)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Human antibodies that specifically bind human TNF alpha
EP0949931B1 (en)	1996-12-06	2008-08-27	Amgen Inc.,	Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
CA2287254A1 (en) *	1997-04-21	1998-10-29	Schering Corporation	Mammalian cytokines; related reagents and methods
US6337072B1 (en)	1998-04-03	2002-01-08	Hyseq, Inc.	Interleukin-1 receptor antagonist and recombinant production thereof
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
US7906481B2 (en)	1998-09-25	2011-03-15	Sciaticon Ab	Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
KR101077001B1 (ko)	1999-01-15	2011-10-26	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US6471961B1 (en)	1999-02-24	2002-10-29	Edward L. Tobinick	Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6419944B2 (en)	1999-02-24	2002-07-16	Edward L. Tobinick	Cytokine antagonists for the treatment of localized disorders
JP3363832B2 (ja)	1999-05-13	2003-01-08	アルプス電気株式会社	薄膜構造体およびその製造方法
WO2001042304A1 (en)	1999-12-10	2001-06-14	Amgen, Inc.	Interleukin-1 receptor antagonist-related molecules and uses thereof
CA2393532A1 (en)	1999-12-10	2001-06-14	Frank J. Calzone	Interleukin-1 receptor antagonist-like molecules and uses thereof
CN1433431A (zh)	1999-12-10	2003-07-30	安姆根有限公司	白介素－1受体拮抗剂样分子及其应用
US20030007971A1 (en)	2000-01-31	2003-01-09	Hideaki Hara	Remedies for ophthalmic diseases
WO2001057082A2 (en)	2000-02-03	2001-08-09	Regeneration Technologies, Inc.	Extraction of growth factors from tissue
US20040026042A1 (en)	2000-04-17	2004-02-12	Edwards Mark Stephen	Method and apparatus for making bristle subassemblies
US20020131954A1 (en)	2000-05-02	2002-09-19	Tobinick Edward L.	Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20010053764A1 (en)	2000-05-12	2001-12-20	Sims John E.	Interleukin-1 inhibitors in the treatment of diseases
US20030026806A1 (en)	2000-10-27	2003-02-06	Amgen Inc.	Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7087224B2 (en)	2000-10-31	2006-08-08	Amgen Inc.	Method of treating anemia by administering IL-1ra
US20030166069A1 (en)	2000-11-28	2003-09-04	Amgen, Inc.	Interleukin-1 receptor antagonist-like molecules and uses thereof
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
CN1549723A (zh)	2001-02-06	2004-11-24	Ĭ��ר��޹�˾	免疫原性减弱的经修饰白介素-1受体拮抗剂(il-1ra)
US20050143333A1 (en)	2001-05-18	2005-06-30	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20030083301A1 (en)	2001-09-06	2003-05-01	Board Of Regents, The University Of Texas System	Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
US7381801B2 (en)	2002-02-13	2008-06-03	Ludwig Institute For Cancer Research	Chimerized GM-CSF antibodies
US6890654B2 (en)	2002-04-18	2005-05-10	Northwestern University	Encapsulation of nanotubes via self-assembled nanostructures
US7029712B1 (en)	2002-07-17	2006-04-18	Biosyntrx Inc	Treatment for dry eye syndrome
PL378879A1 (pl)	2002-12-30	2006-05-29	Amgen Inc.	Terapia skojarzona z czynnikami kostymulującymi
US20050033694A1 (en)	2003-06-03	2005-02-10	United States Postal Service.	System and method for fleet card management
US7261882B2 (en)	2003-06-23	2007-08-28	Reagents Of The University Of Colorado	Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050023872A1 (en)	2003-07-28	2005-02-03	Hetzel Thomas R.	Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion
KR100543466B1 (ko)	2003-11-13	2006-01-20	삼성전자주식회사	영상 보간 장치 및 방법
US7482323B2 (en)	2004-03-04	2009-01-27	The University Of Tennessee Research Foundation	Intracellular interleukin-1 receptor antagonist and uses thereof
US7674464B2 (en)	2004-03-04	2010-03-09	The University Of Tennessee Research Foundation	Intracellular interleukin-1 receptor antagonists
JP2007531738A (ja)	2004-04-02	2007-11-08	アムジエン・インコーポレーテツド	ＩＬ−１ｒａの凝集を低下させる方法
US8618054B2 (en)	2004-05-05	2013-12-31	Valorisation-Rechereche Société en Commandite	Interleukin-1 receptor antagonists, compositions, and methods of treatment
CA2568352C (en)	2004-06-04	2011-09-13	Regeneron Pharmaceuticals, Inc.	Methods of using il-1 antagonists to treat autoinflammatory disease
US7365165B2 (en)	2004-08-17	2008-04-29	Regeneron Pharmaceuticals, Inc.	IL-1 antagonist formulations
US7700318B2 (en) *	2004-08-25	2010-04-20	Amprotein Corporation	Chimeric polypeptide and use thereof
CN101132800A (zh)	2004-11-24	2008-02-27	席拉坎有限责任公司	一种用于眼内药物释出的植入体
BRPI0518762A2 (pt)	2004-12-02	2008-12-09	Domantis Ltd	fusço de droga, conjugado de droga, Ácido nucleico recombinante ou isolado, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir a fusço de droga, composiÇço farmacÊutica, mÉtodo para tratamento de um indivÍduo tendo uma doenÇa inflamatària, uso de um conjugado de droga ou fusço de droga, e, composiÇço de droga
CA2612937C (en)	2005-07-22	2014-05-06	Amgen Inc.	Concentrated protein lyophilates, methods, and uses
JP2009507023A (ja)	2005-09-01	2009-02-19	シェーリングコーポレイション	自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
IL172297A (en)	2005-10-03	2016-03-31	Compugen Ltd	Soluble vegfr-1 variants for the diagnosis of preeclampsia
JP2009512710A (ja)	2005-10-21	2009-03-26	アムジエン・インコーポレーテツド	Ｉｌ−１阻害剤を用いて血管石灰化を抑制する方法
EP2021026A1 (en)	2006-04-14	2009-02-11	Novartis AG	Use of il-i antibodies for treating ophthalmic disorders
WO2007123976A2 (en)	2006-04-18	2007-11-01	The Board Of Trustees Of The Leland Stanford Junior University	Antibody profiling for determination of patient responsiveness
US20100028328A1 (en)	2006-06-12	2010-02-04	Therakine, Ltd.	Topical treatment for diseases of eye surface
US20080095754A1 (en)	2006-10-18	2008-04-24	Burke Susan E	Ophthalmic compositions comprising diglycine
US8399421B2 (en)	2007-03-30	2013-03-19	The Board Of Regents Of The University Of Texas System	Treatment for neuropathic pain due to spinal cord injury
GB0708376D0 (en)	2007-05-01	2007-06-06	Alligator Bioscience Ab	Novel polypeptides and uses thereof
KR20160017119A (ko)	2007-05-29	2016-02-15	노파르티스 아게	항-ｉｌ-1-베타 치료법에 대한 신규 적응증
ATE502114T1 (de)	2007-06-21	2011-04-15	Univ Muenchen Tech	Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
KR101430584B1 (ko)	2007-07-05	2014-08-14	삼성전자주식회사	이동 통신 시스템에서 심 어플리케이션 툴킷을 제공하는장치 및 방법
BRPI0815416A2 (pt)	2007-08-15	2014-10-21	Amunix Inc	Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
EP2187900B1 (en)	2007-08-16	2016-11-09	The Schepens Eye Research Institute, Inc.	Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
WO2009048961A1 (en)	2007-10-08	2009-04-16	Anaphore, Inc.	Trimeric il-1ra
CA3069576A1 (en)	2008-01-09	2009-07-16	The Schepens Eye Research Institute, Inc.	Therapeutic compositions for treatment of ocular inflammatory disorders
WO2010089522A1 (en)	2009-07-16	2010-08-12	Arecor Limited	Stable formulation of a therapeutic protein
US8298533B2 (en)	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
US20120014970A1 (en)	2009-01-09	2012-01-19	Reza Dana	Therapeutic Compositions for Treatment of Corneal Disorders
AU2010203425B2 (en)	2009-01-09	2015-04-09	The Schepens Eye Research Institute, Inc.	Therapeutic compositions for treatment of corneal disorders
CN102395378B (zh)	2009-02-18	2016-01-20	爱昂粒子科学有限责任公司	用于眼科和其他外用或局部应用的双功能共聚物
EP2248518B1 (en)	2009-04-17	2013-01-16	Merz Pharma GmbH & Co. KGaA	Formulation for stabilizing proteins, peptides or mixtures thereof.
US20120269765A1 (en)	2009-07-24	2012-10-25	Garcia K Christopher	Cytokine compositions and methods of use thereof
WO2011028344A2 (en)	2009-08-25	2011-03-10	Amunix Operating Inc.	Interleukin-1 receptor antagonist compositions and methods of making and using same
KR20120093932A (ko)	2009-10-10	2012-08-23	일레븐 바이오테라피틱스, 아이엔씨.	Ｉｌ－１７ 패밀리 사이토카인 조성물들 및 용도들
WO2011063195A2 (en)	2009-11-20	2011-05-26	Dr. Reddy's Laboratories Ltd.	Purification of modified cytokines
WO2011106697A1 (en)	2010-02-25	2011-09-01	Schepens Eye Research Institute	Therapeutic compositions for the treatment of dry eye disease
EP3372617B1 (en)	2010-04-02	2024-07-24	Amunix Pharmaceuticals, Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011163452A2 (en)	2010-06-24	2011-12-29	Eleven Biotherapeutics, Inc.	Treating surface of the eye disorders
PL2598526T4 (pl)	2010-07-29	2019-05-31	Eleven Biotherapeutics Inc	Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1
WO2012103240A2 (en)	2011-01-25	2012-08-02	Eleven Biotherapeutics, Inc.	Receptor binding agents
CN103476933B (zh)	2011-03-14	2016-04-13	弗洛格有限公司	白介素1受体的拮抗剂
US20140341843A1 (en)	2011-07-29	2014-11-20	Eleven Biotherapeutics, Inc.	Purified proteins
CN107693781B (zh)	2013-03-13	2021-11-09	巴扎德制药公司	用于眼部递送的嵌合细胞因子制剂

2011
- 2011-07-29 PL PL11749612.5T patent/PL2598526T4/pl unknown
- 2011-07-29 HU HUE18191564A patent/HUE063115T2/hu unknown
- 2011-07-29 ES ES11749612T patent/ES2701405T3/es active Active
- 2011-07-29 EP EP11749612.5A patent/EP2598526B1/en active Active
- 2011-07-29 CA CA2806438A patent/CA2806438C/en active Active
- 2011-07-29 ES ES18191564T patent/ES2952394T3/es active Active
- 2011-07-29 SG SG2013006697A patent/SG187231A1/en unknown
- 2011-07-29 JP JP2013522011A patent/JP6030554B2/ja active Active
- 2011-07-29 CN CN201180047508.1A patent/CN103221422B/zh active Active
- 2011-07-29 LT LTEP11749612.5T patent/LT2598526T/lt unknown
- 2011-07-29 MX MX2013001107A patent/MX360097B/es active IP Right Grant
- 2011-07-29 BR BR112013003646-0A patent/BR112013003646B1/pt active IP Right Grant
- 2011-07-29 RU RU2017132694A patent/RU2754957C2/ru active
- 2011-07-29 AU AU2011283669A patent/AU2011283669A1/en not_active Abandoned
- 2011-07-29 NZ NZ605928A patent/NZ605928A/en unknown
- 2011-07-29 RU RU2013108836/10A patent/RU2013108836A/ru not_active Application Discontinuation
- 2011-07-29 EP EP18191564.6A patent/EP3470421B9/en active Active
- 2011-07-29 HR HRP20181446TT patent/HRP20181446T1/hr unknown
- 2011-07-29 WO PCT/US2011/045995 patent/WO2012016203A1/en not_active Ceased
- 2011-07-29 EP EP23157789.1A patent/EP4219538A3/en active Pending
- 2011-07-29 PL PL18191564.6T patent/PL3470421T3/pl unknown
- 2011-07-29 KR KR1020137005337A patent/KR102080704B1/ko active Active
- 2011-07-29 SI SI201131571T patent/SI2598526T1/sl unknown
- 2011-07-29 HU HUE11749612A patent/HUE041590T2/hu unknown
- 2011-07-29 DK DK11749612.5T patent/DK2598526T3/en active
- 2011-07-29 US US13/812,582 patent/US8853150B2/en active Active
- 2011-07-29 HR HRP20230776TT patent/HRP20230776T1/hr unknown
- 2011-07-29 CN CN201710129141.7A patent/CN107337735B/zh active Active
2013
- 2013-01-28 IL IL224435A patent/IL224435B/en active IP Right Grant
2014
- 2014-08-15 US US14/460,563 patent/US9458216B2/en active Active
2015
- 2015-07-17 ZA ZA2015/05145A patent/ZA201505145B/en unknown
2016
- 2016-08-12 AU AU2016213845A patent/AU2016213845B2/en active Active
2018
- 2018-05-08 HK HK18105915.1A patent/HK1246327A1/zh unknown
- 2018-05-23 IL IL259547A patent/IL259547B/en active IP Right Grant
- 2018-10-18 AU AU2018250431A patent/AU2018250431A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR112013003646B1 (pt)	2021-09-08
CA2806438C (en)	2021-04-13
JP2013535204A (ja)	2013-09-12
KR20130136447A (ko)	2013-12-12
RU2754957C2 (ru)	2021-09-08
HUE063115T2 (hu)	2023-12-28
NZ605928A (en)	2015-02-27
EP2598526B1 (en)	2018-09-05
CN103221422B (zh)	2017-03-29
HUE041590T2 (hu)	2019-05-28
HK1246327A1 (zh)	2018-09-07
HRP20230776T1 (hr)	2023-10-27
US8853150B2 (en)	2014-10-07
KR102080704B1 (ko)	2020-02-24
EP4219538A3 (en)	2023-08-09
CN103221422A (zh)	2013-07-24
PL3470421T3 (pl)	2023-10-23
RU2017132694A (ru)	2019-02-06
ES2701405T3 (es)	2019-02-22
AU2011283669A1 (en)	2013-02-07
CA2806438A1 (en)	2012-02-02
AU2018250431A1 (en)	2018-11-15
MX360097B (es)	2018-10-22
RU2017132694A3 (pl)	2020-12-22
HRP20181446T1 (hr)	2018-11-02
EP2598526A1 (en)	2013-06-05
CN107337735B (zh)	2021-06-22
DK2598526T3 (en)	2018-11-19
US20130209396A1 (en)	2013-08-15
US20150087818A1 (en)	2015-03-26
CN107337735A (zh)	2017-11-10
US9458216B2 (en)	2016-10-04
WO2012016203A1 (en)	2012-02-02
EP3470421B1 (en)	2023-06-07
JP6030554B2 (ja)	2016-11-24
BR112013003646A2 (pt)	2017-07-04
IL259547B (en)	2020-04-30
ZA201505145B (en)	2015-09-30
EP3470421C0 (en)	2023-06-07
MX2013001107A (es)	2013-06-18
IL224435B (en)	2018-06-28
SG187231A1 (en)	2013-02-28
EP3470421A1 (en)	2019-04-17
AU2016213845A1 (en)	2016-09-29
SI2598526T1 (sl)	2018-10-30
PL2598526T3 (pl)	2019-02-28
EP3470421B9 (en)	2023-10-04
LT2598526T (lt)	2018-10-10
ES2952394T3 (es)	2023-10-31
RU2013108836A (ru)	2014-09-10
EP4219538A2 (en)	2023-08-02
AU2016213845B2 (en)	2018-07-19
IL259547A (en)	2018-07-31

Publication	Publication Date	Title
PL2598526T4 (pl)	2019-05-31	Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1
EP2739345A4 (en)	2015-04-15	ELECTRODE COATED WITH AN IL-1 RECEPTOR ANTAGONIST AND USES THEREOF
HRP20190137T1 (hr)	2019-03-22	Stabilne formulacije polipeptida i njihova uporaba
DK2821407T3 (da)	2017-01-02	Piperidinoncarboxamidazaindan-cgrp receptorantagonister
SMT201600078B (it)	2016-04-29	Antagonista del recettore per cgrp
PL2513093T3 (pl)	2015-03-31	Nowi antagoniści receptora CCR2 i ich zastosowanie
PL2648726T3 (pl)	2018-10-31	Policykliczny antagonista lpa1 i jego zastosowania
HUE047228T2 (hu)	2020-04-28	Stabil heterodimer antitest-kialakítás az FC doménben mutációval
PL3214091T3 (pl)	2019-03-29	Zastosowanie komórek T modyfikowanych chimerycznymi receptorami antygenowymi do leczenia nowotworów
BR112013010988A2 (pt)	2016-07-26	composição fluída e uso
PL2903754T3 (pl)	2017-12-29	Łyżka i jej zastosowanie
EP2665707A4 (en)	2015-01-14	ANTAGONISTS OF THE MINERALOCORTICOID RECEPTOR
FI20095529A0 (fi)	2009-05-12	Probioottien uusi käyttö
IL250606A0 (en)	2017-04-30	D2 antagonists, methods of synthesis and methods of use
ZA201306744B (en)	2014-11-26	Antagonists of the interleukin-1 receptor
SMT201500296B (it)	2016-01-08	Antagonisti del recettore trpm8
PL2612904T3 (pl)	2017-07-31	Kompozycje przeciwpróchnicze i probiotyki/prebiotyki
SMT201600332B (it)	2016-11-10	Composizioni e metodi per l’aumento dell’attivitàtelomerasica
EP2563123A4 (en)	2013-10-23	NEW BETA-3 ADRENERGE RECEPTOR AGONISTS
NO343662B1 (no)	2019-04-29	Strømningsmåling
CR20130133A (es)	2013-08-29	Composiciones de anticuerpo y mètodos de uso
CO6781486A2 (es)	2013-10-31	Compuestos y su uso
EP2527004A4 (en)	2016-12-28	ULTRASONIC PROBE
FI20105197L (fi)	2011-09-02	Aineiden välisiä rajapintoja ilmaiseva sondi
PL2793883T3 (pl)	2018-09-28	Antagoniści trpm8